ENDRA Life Sciences (NDRA) had its "sell (e+)" rating reaffirmed by
Weiss Ratings.
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value
ENDRA's TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care [Yahoo! Finance]
ENDRA’s TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care